In a phase 1 trial, sorafenib was used as a maintenance therapy in patients with FLT3-ITD AML (started between D45 and D120 after HSCT), resulting in a 1-year progression-free survival (PFS) of 85% and 1-year OS of 95% [38]. The gene discussed is FLT3; the disease is acute myeloid leukemia.